Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Erytech Pharma (NASDAQ: ERYP).

Full DD Report for ERYP

You must become a subscriber to view this report.


Recent News from (NASDAQ: ERYP)

ERYTECH Reports First Quarter 2018 Financial Results and Provides Business Update
Finalized Phase 3 trial design for eryaspase in second line pancreatic cancer; on track for expected start of patient enrollment in Q3 Selected triple-negative breast cancer as the next solid tumor indication; preparing Phase 2 trial with expected start of patient enrollment in Q3 ...
Source: GlobeNewswire
Date: May, 14 2018 16:30
ERYTECH Strengthens Executive Team with the Appointment of Alex Dusek as VP of Commercial Strategy
LYON, France, May 14, 2018 (GLOBE NEWSWIRE) -- ERYTECH Pharma (Euronext:ERYP) (Nasdaq:ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, announced that it has appointed Alex Dusek as its...
Source: GlobeNewswire
Date: May, 14 2018 01:30
ERYTECH to Host First Quarter 2018 Conference Call and Business Update
LYON, France, May 09, 2018 (GLOBE NEWSWIRE) -- ERYTECH Pharma (Euronext Paris:ERYP) (Nasdaq:ERYP) , a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today announced that it will host its 2018 fi...
Source: GlobeNewswire
Date: May, 09 2018 01:30
Institutional Top Ideas Series: Baker Brothers
In the last entry of this series, we took a look at top ideas from Scopia Capital Management (whose performance significantly exceeded that of the IBB during the time frame we looked at). We also took into account the fact that they are a long/short market neutral fund with several outsize...
Source: SeekingAlpha
Date: April, 25 2018 05:17
ERYTECH Announces Filing of 2017 "Document de Référence" and 2017 Annual Report on Form 20-F
LYON, France, April 24, 2018 (GLOBE NEWSWIRE) -- ERYTECH Pharma (Euronext Paris:ERYP) (Nasdaq:ERYP) , the clinical-stage biopharmaceutical company developing innovative therapies for severe forms of cancer and orphan diseases based on its proprietary ERYCAPS platform, encapsulating ther...
Source: GlobeNewswire
Date: April, 24 2018 16:30
ERYTECH to Present Results from Phase I Trial of eryaspase in ALL and New Pre-clinical Data at AACR 2018
LYON, France, April 12, 2018 (GLOBE NEWSWIRE) -- ERYTECH Pharma (Euronext Paris:ERYP) (Nasdaq:ERYP) , a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today announced that it will present full r...
Source: GlobeNewswire
Date: April, 12 2018 01:30
Erytech Pharma (ERYP) Presents At 38th Annual Cowen And Company Healthcare Conference - Slideshow
The following slide deck was published by Erytech Pharma S.A. ADS in conjunction with this Read more ...
Source: SeekingAlpha
Date: March, 15 2018 14:34
Erytech Pharma S.A. ADS 2017 Q4 - Results - Earnings Call Slides
The following slide deck was published by Erytech Pharma S.A. ADS in conjunction with their 2017 Q4 earnings Read more ...
Source: SeekingAlpha
Date: March, 14 2018 13:24
Key healthcare events next week (continued)
Additional presenters at Leerink's Global Healthcare Conference in New York, February 14 - 15: More news on: Epizyme, Intra-Cellular Therapies Inc., Tocagen Inc, Healthcare stocks news, Read more ...
Source: SeekingAlpha
Date: February, 09 2018 12:37
Stocks To Watch: Welcome To The Party Rising Rates
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. Investors might have a little more work to do now that higher interest rates have c...
Source: SeekingAlpha
Date: February, 03 2018 08:45

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-05-1720.0020.0020.0020.00575

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-08-159069612.9310Cover
2018-08-1055065084.6154Short
2018-08-0310020050.0000Short
2018-08-02168168100.0000Short
2018-07-30130130100.0000Short

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on ERYP.


About Erytech Pharma (NASDAQ: ERYP)

Logo for Erytech Pharma (NASDAQ: ERYP)

Not available

 

Contact Information

     

     

    Current Share Structure

       



      Daily Technical Chart for (NASDAQ: ERYP)

      Daily Technical Chart for (NASDAQ: ERYP)


      Stay tuned for daily updates and more on (NASDAQ: ERYP)

      It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

      More to come on (NASDAQ: ERYP)

      Do your DD and if you choose, be ready to go!


       

      The Research: All source information contained in this email is from the public sources mentioned below.

       

       
       

      Thank you

      DD Report
      @DDReports

       

       


      Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in ERYP is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received up to $100,000 worth of crypto currency from a non-affiliated third party for the publication and circulation of this report. DD Report does not own any shares of ERYP and does not buy, sell, or trade any shares of ERYP. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: http://dd.report/disclaimer/